Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































States Can’t Wait – Pennsylvania Leads New Round of State Laws to Tackle Drug Costs
/in Prescription Drug Pricing Blogs, Featured News Home Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Trish RileyLast week, Pennsylvania State Sen. Senator Thomas Killion submitted a first-in-the-nation proposal to reduce drug costs in his state using a new international drug pricing model law developed by the National Academy for State Health Policy (NASHP). The International Reference Rates model law “imports” Canadian prices, which can cost 80 percent less than in the […]
States Save on Rx Spending by Using Reverse Auctions for Pharmacy Benefit Manager Service Procurement
/in Prescription Drug Pricing New Jersey Blogs, Featured News Home Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Amanda AttiyaA 2016 New Jersey law gave the state flexibility to share bid information submitted by all pharmacy benefit managers (PBMs) in order to incentivize the PBMs to submit lower offers in additional rounds of bidding – a process known as a reverse auction. While reverse auctions have been used historically to procure goods, New Jersey’s […]
#NASHPCONF20 Highlighted States’ Creativity in Addressing Equity, Bolstering Health Care, and Preserving Safety Nets during COVID-19
/in #NASHPCONF20 Blogs, Featured News Home Behavioral/Mental Health and SUD, Chronic and Complex Populations, Consumer Affordability, Cost, Payment, and Delivery Reform, COVID-19, Health Coverage and Access, Health Equity, Health System Costs, Long-Term Care, Making the Case for Action, Population Health, Prescription Drug Pricing, Social Determinants of Health, State Insurance Marketplaces, State Rx Legislative Action, Value-Based Purchasing /by Trish RileyLast week, over 1,000 state health policy leaders and others from every state joined the National Academy for State Health Policy’s (NASHP) first-ever virtual state health policy conference to discuss a path forward during an unrelenting pandemic and profound budget challenges. As one state official noted, “This was a chance to lift my eyes from […]
Why Pay More? NASHP’s New Model Law Uses International Drug Pricing to Lower Costs
/in Model Legislation and Contracts, Prescription Drug Pricing Blogs, Featured News Home Administrative Actions, Legal Resources, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Trish RileyFrustrated that their constituents pay far more for prescription drugs than residents of other nations, many state policymakers have embraced Canadian drug importation. Six groundbreaking states, led by Vermont, have enacted laws to enable importation but still need federal approval to begin. Proposed rules, which President Trump recently touted in an Executive Order, still need […]
Q&A: A Model Act to Reduce Prescription Drug Costs Using International Pricing
/in Policy Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffHow does this model act use international pricing to reduce prescription drug costs? Drug prices in other countries are often many times lower than in the United States. This model legislation link determines payment rates for certain prescription drugs based on international prices, and establishes the referenced rate as the upper payment limit for payers […]
The National Academy for State Health Policy’s Proposal for State-Based International Reference Pricing for Prescription Drugs
/in Policy Administrative Actions, Legal Resources, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Rachel E. SachsQ&A: An Act to Protect Consumers from Unsupported Prescription Drug Price Increases
/in Model Legislation and Contracts, Prescription Drug Pricing Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffWhat is this model designed to do? This model fines pharmaceutical manufacturers for certain price increases that are unsupported by clinical evidence and uses that revenue to provide cost assistance to consumers. The model impacts frequently prescribed, high-cost drugs, such as Humira, whose price doubled from $19,000 to $38,000 between 2012 and 2018. The law […]
NASHP’s New Model Law Penalizes Drug Manufacturers for Unsupported Price Hikes
/in Model Legislation and Contracts, Prescription Drug Pricing Blogs, Featured News Home Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Trish Riley and Jennifer ReckUnpredictable and unrelenting drug price increases drive up health insurance premiums and challenge states’ public purchasers as they weigh escalating costs against balanced budget requirements. The National Academy for State Health Policy’s (NASHP) newest model law, an Act to Protect Consumers from Unsupported Price Increases on Prescription Drugs, levies hefty fines on manufacturers that impose […]
An Act to Protect [Name of State] Consumers from Unsupported Price Increases on Prescription Drugs
/in Model Legislation and Contracts, Prescription Drug Pricing Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffSection 1. Statement of Legislative Intent; Purpose The purpose of this Chapter is to protect the safety, health and economic well-being of [Name of State] people by guarding them from the negative and harmful impact of unsupported price increases for prescription drugs. In enacting this Act, the legislature finds that: 1) Access to […]
New NASHP Model Act Licenses Pharmaceutical Sales Reps to Curb Drug Spending
/in Prescription Drug Pricing Blogs, Featured News Home Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer Reck and Trish RileyGetting a grip on pharmaceutical manufacturers’ pricing strategies is a 2020 priority for the National Academy for State Health Policy (NASHP), but how drugs are marketed also significantly impacts spending on drugs. In 2016, pharmaceutical companies spent $6 billion on direct-to-consumer advertising, but a whopping $20.3 billion to market their brand name drugs to health […]